GI Innovation지아이이노베이션
358570 · KOSDAQ · ₩358570 · 지아이이노베이션
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩68
vs the current price (₩7,140)
- Enterprise value
- −₩33B
- Equity value
- ₩4.4B
- WACC
- 8.1%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 99% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- No operating margin up to 90% gets the model to today's price at these growth assumptions.
- Margins ranged from −198,751.9% to −696.4% over the last 4 years, so this is a cyclical business. The model uses the average; the price may be set by where the cycle is now. Try the margin fade option.
- In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.
- The group includes a financial business (an insurer, bank or broker), whose investments and minority shareholders are left out here. A sum-of-the-parts view usually fits groups like this better.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩165
- −97.7%
- Base
- ₩68
- −99.1%
- Bull
- —
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (−20.0%).
Revenue growth
- 18.6%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (18.6% a year, annual reports), fading to 3% by year 5.
- 14.7%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (18.6% a year, annual reports), fading to 3% by year 5.
- 10.8%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (18.6% a year, annual reports), fading to 3% by year 5.
- 6.9%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (18.6% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (18.6% a year, annual reports), fading to 3% by year 5.
Business
- -20%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 4 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 64.5%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 80.6%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 40%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.08%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-29.
- 0.73
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.6, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.58%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩5.5B
- Net debt (borrowings and leases − cash and deposits)
- −₩38B
- Shares
- 64,516,006
- Share price
- ₩7,140
- Market cap
- ₩461B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩5.3B | ₩24M | ₩5.8B | ₩6.5B | ₩7.5B | ₩8.3B | ₩8.9B | ₩9.1B |
| Growth | 52.0% | −99.5% | 23,943.4% | 18.6% | 14.7% | 10.8% | 6.9% | 3.0% |
| EBIT | −₩53B | −₩48B | −₩41B | −₩1.3B | −₩1.5B | −₩1.7B | −₩1.8B | −₩1.8B |
| EBIT margin | −1,002.2% | −198,751.9% | −696.4% | −20.0% | −20.0% | −20.0% | −20.0% | −20.0% |
| After-tax EBIT | −₩39B | −₩35B | −₩29B | −₩946M | −₩1.1B | −₩1.2B | −₩1.3B | −₩1.3B |
| + Depreciation | — | — | — | ₩4.2B | ₩4.8B | ₩5.3B | ₩5.7B | ₩5.9B |
| − Capital spending | ₩579M | ₩25M | ₩7.5B | ₩5.3B | ₩6B | ₩6.7B | ₩7.1B | ₩7.4B |
| − Working capital | −₩34B | −₩20B | −₩1.9B | ₩409M | ₩384M | ₩323M | ₩229M | ₩106M |
| Free cash flow | — | — | — | −₩2.4B | −₩2.7B | −₩2.9B | −₩2.9B | −₩2.9B |
| Discount factor | — | — | — | 0.925 | 0.856 | 0.792 | 0.732 | 0.678 |
| Present value | — | — | — | −₩2.2B | −₩2.3B | −₩2.3B | −₩2.2B | −₩2B |
Terminal value −₩33B, worth −₩23B today: 67% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩1,498 a share)Now 4.77× | ₩7,7185.15× | ₩13,0498.71× | ₩20,19213.5× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2023, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 7.1% | ₩57 | ₩19 | — | — | — |
| 7.6% | ₩94 | ₩62 | ₩25 | — | — |
| 8.1% | ₩125 | ₩99 | ₩68 | ₩31 | — |
| 8.6% | ₩153 | ₩130 | ₩104 | ₩73 | ₩37 |
| 9.1% | ₩177 | ₩157 | ₩135 | ₩109 | ₩78 |
Now (TTM)
- Market cap
- ₩461B
- Enterprise value
- ₩423B
- P/E
- —
- P/B
- 4.8×
- P/S
- 83.8×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Price | ₩17,640 | ₩7,353 | ₩10,038 |
| Market cap | ₩1.1T | ₩474B | ₩648B |
| P/E | — | — | — |
| P/B | 9.8× | 16.3× | 9.0× |
| P/S | 194.9× | 19,536.1× | 121.8× |
| EV/EBITDA | — | — | — |
| Dividend yield | 0.0% | — | — |
Loading data for this company — check back soon
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| GI Innovation | — | 4.8× | 83.8× | — | 0.0% |
| Samsung Biologics | 32.0× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.9× | 2.5× | 9.0× | — | 0.0% |
| Alteogen | 80.5× | 29.0× | 61.2× | — | 0.1% |
| SK biopharmaceuticals | 14.7× | 5.8× | 6.8× | — | 0.0% |
| Yuhan | 24.0× | 2.4× | 2.5× | 31.3× | 0.8% |
| HLB | — | 15.7× | 55.6× | — | 0.0% |
| Similar companies (median) | 27.9× | 6.7× | 11.5× | 31.3× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: GI Innovation / 지아이이노베이션 / 358570 / KRX:358570
Source: KRX statistical information